| Date | Title | Description |
| 30.07.2024 | DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report | Châtillon, France, July 30, 2024
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-st... |
| 08.03.2024 | DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document | - |
| 07.03.2024 | DBV Technologies Reports Full Year 2023 Financial Results and Business Update | - |
| 04.03.2024 | Allergy Immunotherapy Market Demand Analysis and Opportunity Outlook 2030|Adamis Pharmaceuticals,HollisterStier Allergy | Allergy Immunotherapy
Allergy Immunotherapy Market Review: All Eyes on 2024 Outlook
Stay up to date with Allergy Immunotherapy Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.”
—... |
| 04.03.2024 | DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 | Montrouge, France, March 4, 2024
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmac... |
| 04.03.2024 | DBV Technologies présentera ses résultats financiers pour l’exercice 2023 et fera le point sur ses activités le 7 mars 2024. | Montrouge, France, le 4 mars (22h30 CET) 2024
DBV Technologies présentera ses résultats financiers pour l’exercice 2023 et fera le point sur ses activités le 7 mars 2024.
DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock... |
| 09.06.2022 | DBV Technologies Announces Private Placement Financing of $194 Million | Montrouge, France, June 9, 2022
DBV Technologies Announces Private Placement Financing of $194 Million
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, to... |
| 04.05.2022 | DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) | Montrouge, France, May 5, 2022
DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (t... |
| 26.10.2021 | DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments - Form 8-K | DBV Technologies Reports Third Quarter 2021 Financial
Results and Recent Regulatory Developments
DBV Technologies S.A. (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today repor... |
| 28.04.2021 | DBV TECHNOLOGIES S.A.
DBV Technologies S A : AGM 2021 – US Proxy Statement | DBV Technologies S.A.
Proxy Statement for the
2021 Annual Combined General Meeting of Shareholders
Dear Fellow Shareholders,
DBV Technologies was founded on the belief that children with food allergies, their families, and the allergists wh... |
| 18.03.2020 | FDA cancels AdCom meeting for DBV’s peanut allergy patch, citing efficacy concerns | Shares of DBV were down 56% on the Euronext Paris when that market closed Tuesday. They were also down 54% on the Nasdaq mid-day Tuesday.
“We appreciate the ongoing dialogue with the FDA and look forward to further discussions in the coming... |
| 17.03.2020 | In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions | Another regulatory setback has strayed DBV Therapeutics’s peanut allergy patch off the path to approval.
On Monday, the company disclosed that the FDA, which is currently reviewing the marketing application for the... |
| 11.12.2019 | Oral immunotherapy can be a game changer for many with food allergies | Food allergies upend lives. In children, food allergies can scale back or completely stop participation in birthday parties, organized sports, and summer camps. Parents may need to reduce their work hours and homeschool their children. For ... |
| 06.10.2019 | DBV Technologies’ peanut allergy patch gets FDA review | The FDA is expected to decide whether to approve the application by Aug. 5 of next year and has signaled it will hold an advisory committee meeting to discuss it, the company said. DBV had submitted its approval application for the product ... |
| 20.06.2019 | Assessing the value of new food allergy treatments must include quality of life | Walk into any classroom in America today and you’ll likely find at least two children with a food allergy. More than 40% of such children have experienced a serious allergic reaction such as anaphylaxis, a severe, potentially life-threateni... |
| 04.01.2019 | Atara seeks new CEO as Isaac Ciechanover exits; AstraZeneca's Mark Mallon tapped to replace Peter Hecht at Ironwood | → In an abrupt departure, Isaac Ciechanover is stepping down from Atara Biotherapeutics $ATRA, the T cell therapy company that he founded in 2012 in honor of his mother. The South San Francisco biotech gave no reason for th... |
| 04.11.2016 | Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table | Greg Behar, CEO, Nestlé Health Science
Nestlé Health Science is making another big investment in an emerging biotech company. The Brisbane, CA-based Aimmune $AIMT is selling a whopping $145 million stake in the company to ... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 21.07.2015 | DBV Technologies Closes $281.5M Public Offering | DBV Technologies, (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a French clinical-stage specialty biopharmaceutical company, closed a $281.5m public offering.
The gross proceeds included an underwritten public offering o... |
| 29.01.2015 | A peanut allergy cure might be on the horizon | After a 18-month period, more than 80 percent of the 28 kids given the treatment became tolerant to peanuts. These results are pretty astonishing, but the researchers don’t know exactly how long the effects last quite yet. Still, major prog... |
| 05.01.2011 | DBV Technologies Secures €19,4M in Series C Financing Round | DBV Technologies, a Paris, France-based biotechnology company whose products are designed to epicutaneously deliver allergens for Epicutaneous Immunotherapy (EPIT) against food allergies such as peanut and milk, has secured $25.5m (€19,4m) ... |
| - | DBV Technologies’ peanut allergy patch gets FDA review | The Food and Drug Administration has accepted an application for another drug to treat children with peanut allergy.
Montrouge, France-based DBV Technologies said Friday that the FDA had accepted its application for Viaskin Peanut, a once-d... |
| - | A peanut allergy cure might be on the horizon | Food allergies are a serious issue for many people – peanuts being one of the most problematic. And for some reason it’s getting worse, as IFLScience spelled out:
Food allergies are on the rise in developed nations, but scientists aren’t su... |
| - | FDA cancels AdCom meeting for DBV’s peanut allergy patch, citing efficacy concerns | The Food and Drug Administration has called off the advisory committee meeting it had scheduled for the middle of May to discuss a drug to treat peanut allergy due to questions about its efficacy.
Montrouge, France-based DBV Technologies sa... |
